Target assessment for antiparasitic drug discovery.
Drug discovery is a high-risk, expensive and lengthy process taking at least 12 years and costing upwards of US$500 million per drug to reach the clinic. For neglected diseases, the drug discovery process is driven by medical need and guided by pre-defined target product profiles. Assessment and prioritisation of the most promising targets for entry into screening programmes is crucial for maximising the chances of success. Here, we describe criteria used in our drug discovery unit for target assessment and introduce the 'traffic-light' system as a prioritisation and management tool. We hope this brief review will stimulate basic scientists to acquire additional information necessary for drug discovery.
Frearson
Julie A
JA
Drug Discovery Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.
Wyatt
Paul G
PG
Gilbert
Ian H
IH
Fairlamb
Alan H
AH
D000818:Animals; D000977:Antiparasitic Agents / Q000494:pharmacology*; D002626:Chemistry, Pharmaceutical; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000191:economics / Q000379:methods; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D010271:Parasites / Q000187:drug effects*; D010272:Parasitic Diseases / Q000188:drug therapy*; D021261:Parasitic Sensitivity Tests; D010597:Pharmacogenetics; D012107:Research Design; D016896:Treatment Outcome
D000977:Antiparasitic Agents